- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
The practical protocols on viral clearance study for the application
-
- MURAI Katsushi
- Japanese Red Cross Plasma Fractionation Center
-
- URAKUBO Tomonari
- Kyowa Hakko Kogyo Co., Ltd.
-
- NISHIDA Yasutake
- Kyowa Hakko Kogyo Co., Ltd.
-
- KOH Enki
- Nihon Pharmaceutical Co., Ltd.
-
- SUGAWARA Keishin
- The Chemo-Sero-Therapeutic Research Institute
-
- OKAMURA Motoyoshi
- Pharmatelier Inc.
-
- ODA Masahiro
- Nihon Pall Ltd.
-
- KAWAMATA Osamu
- SRL Inc.
-
- KOSUGI Kimihiko
- Nihon Millipore KK
-
- SHIOMI Tetsuji
- Wako pure chemical industries, Ltd.
-
- TAKAHASHI Hideharu
- Charles River Japan, Inc.
-
- TONOMORI Shunsuke
- LSG Corporation
-
- HAYASHI Hideki
- Sartorius Stedim Japan KK
-
- MARUYAMA Yuichi
- M's Science Corporation
Bibliographic Information
- Other Title
-
- 申請のための具体的なウイルスクリアランス試験プロトコール 日本PDA製薬学会バイオウイルス委員会ウイルスクリアランス分科会
- PDA Japan, Bio-virus safety committee, viral clearance subcommittee
- 日本 PDA 製薬学会 バイオウイルス委員会ウイルスクリアランス分科会
Search this article
Description
The Bio-virus safety committee, one of the committees of the Parental Drug Association Japan (PDA Japan), has discussed various concerns on biopharmaceuticals from scientific, technical and regulatory perspective. One of the most significant concerns is the risk of viral contamination into the products. This risk should be addressed, as required per the international regulations, by minimizing to use raw materials sourced from animal origin and by performing viral clearance studies in order to evaluate capability of purification processing to reduce and/or inactivate known and/or adventitious viruses. The Bio-virus safety Committee has reported the conclusions of discussion how to prepare and qualify cell bank system as one of raw materials and how much Log Reduction Value (LRV) should be targeted in virus clearance studies in the annual conference of the PDA Japan in 20051). The Bio-virus safety committee has discussed the practical experimental procedures for viral clearance studies since 2006 and reported the conclusions in the annual conference of the PDA Japan in 2007. In this report, standardized and practical experimental procedures for viral clearance studies are shown, considering not only requirements for submission to regulatory agencies but also experimental technique. In addition, trouble shooting based upon experiences of the members, information regarding Contract Research Organizations (CROs), reference of international guidelines, and worksheets of viral clearance study are provided.<br>
Journal
-
- PDA Journal of GMP and Validation in Japan
-
PDA Journal of GMP and Validation in Japan 9 (1), 6-31, 2007
Parenteral Drug Association Japan Chapter
- Tweet
Details 詳細情報について
-
- CRID
- 1390001204473467520
-
- NII Article ID
- 130004493547
-
- DOI
- 10.11347/pda.9.6
-
- ISSN
- 18811728
- 13444891
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- CiNii Articles
-
- Abstract License Flag
- Disallowed